Join Tom and Mike as they share an important update on Tom's prostate cancer journey. In this video, they discuss Tom's ...

The second most common cancer among men is prostate cancer, affecting 1 in 8 men. Prostate cancer is treatable, in most cases, when the cancer remains localized to the prostate gland. But if the ...

Erleada plus ADT may provide limited benefits for mCSPC patients with fewer bone metastases, affecting PFS2 and OS outcomes. Baseline bone metastasis count could guide treatment optimization for mCSPC ...

The Phase 2 trial, called ANDROMEDA, is the first study to directly compare two types of PSMA-targeted radiopharmaceuticals when used alongside stereotactic body radiotherapy (SBRT), a focused form of ...

Daily scans taken during prostate cancer radiotherapy could be repurposed to guide changes to treatment, reducing the risk of side effects, a study suggests. Using AI, scientists found that images ...

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...